Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
  • Science
    • Dark biodiversity
    • New antimicrobials
    • Beyond antimicrobials
  • R&D
    • Innovation engine overview
    • Extracting microbial biodiversity
    • Screening for new activity
    • Active compound characterization
    • Preindustrial production
    • Preclinical development
    • Clinical development
  • Technologies
    • Technology platform overview
    • Biodiversity farming
    • Activity testing
    • Advanced analytics
    • Synthetic biology
    • Data Science
    • Fermentation engineering
    • Bioprocess engineering
  • Pipeline
    • Pipeline overview
    • DNV3837
    • DASMA
  • Partnering
    • New antimicrobials
    • Beyond antimicrobials
  • Investors
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News
    • Press releases
    • Events
    • Media
  1. Home
  2. News

Press releases

26.09.2019

2019 Half-year consolidated results: Deinove’s progress coming to fruition

Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections...
23.09.2019

Integration of CRISPR-cas9 technology to accelerate the discovery of innovative antibiotics

DEINOVE strengthens its expertise in the genetic engineering of rare and varied microorganisms to accelerate the discovery and optimization...
18.09.2019

The efficacy of Hebelys® once again demonstrated and promoted in the International Journal of Cosmetic Science

New in vitro and clinical efficacy data have been published; Sphingomonas hydrophobicum extract, the active substance of Hebelys®,...
09.07.2019

Issuance of notes convertible into new shares for a maximum amount of €15M. Issuance of a first €2.2 million tranche

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...
24.06.2019

DNV3681's exceptional activity against bioterrorist threats presented at ASM Microbe 2019

Major Steven Zumbrun (USAMRIID [1] , U.S. Department of Defense) presented data on the in vitro assessment of DNV3681 against pathogens...
11.06.2019

DEINOVE and AVRIL completing the development of a natural feed additive

The tests aimed at validating the dosage required have confirmed a very good efficacy of the ingredient The teams are working to develop a...
05.06.2019

DEINOVE & Dow sign a collaboration agreement for the development of a new cosmetic active ingredient

Dow has selected an extract belonging to the DEINOVE proprietary strains’ bank to launch a new cosmetic active ingredient for skin care...
21.05.2019

Anne ABRIAT-HEMMENDINGER appointed to the Board of Directors of DEINOVE

Her proven experience in the beauty industry, particularly within the L'Oréal Group, will be a key asset in DEINOVE's innovation approach...
20.05.2019

The US Department of Defense and Deinove will present impactful R&D results during the coming ASM 2019

The USAMRIID (United States Army Medical Research Institute of Infectious Diseases) evaluated DNV3681 against Bacillus anthracis that...
16.05.2019

DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837

Having reached a sufficient number of clinical centers, Phase II clinical trial testing the antibiotic candidate DNV3837 in Clostridioides[...
  • « first
  • ‹ previous
  • …
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • next ›
  • last »

News

  • Press releases
  • Events
  • Media
  • Careers
  • Contact
  • Legal Info
  • Site map
  • Privacy Policy

Follow us

    

Stay in touch

Subscribe to our newsletter

Contact us

Location

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home